title: Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
abstract: A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma. Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months. During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.
authors.affiliation: Department of Dermatology, Tuberous Sclerosis Center, Ludwig-Maximilian-University Munich, Gemany. ralf.wienecke@med.uni-muenchen.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Wienecke
authors.forename: Ingrid
authors.initials: I
authors.lastname: Fackler
authors.forename: Ulrich
authors.initials: U
authors.lastname: Linsenmaier
authors.forename: Karin
authors.initials: K
authors.lastname: Mayer
authors.forename: Thomas
authors.initials: T
authors.lastname: Licht
authors.forename: Matthias
authors.initials: M
authors.lastname: Kretzler
mesh_terms: D000328:Adult; D018207:Angiomyolipoma / Q000188:drug therapy* / Q000209:etiology; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000150:complications*
chemical_list: D000903:Antibiotics, Antineoplastic; D020123:Sirolimus